Chronic obstructive pulmonary disease (COPD) is a debilitating condition characterised by
progressive, irreversible airflow limitation. The economic and social burden of the disease is …

Fixed dose combination (FDC) dual bronchodilators that co‐administer a long acting β2‐
adrenoceptor agonist (LABA) and a long acting muscarinic antagonist (LAMA) are a new …

Introduction Bronchodilators are the cornerstone of chronic obstructive pulmonary disease
(COPD) therapy and long-acting muscarinic antagonists (LAMAs) as a mono or combination …

The most widely used maintenance therapies in chronic obstructive pulmonary disease
(COPD) are long-acting muscarinic antagonists (LAMAs), and a number of these drugs are …

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long …

Through application of our multivalent approach to drug discovery we previously reported
the first discovery of dual pharmacology MABA bronchodilators, exemplified by 1. Herein we …

Because there is a solid pharmacological rationale based on positive interactions between
long‐acting muscarinic receptor antagonists (LAMAs) and long‐acting β‐agonists (LABAs) …

Highlights•Asthma therapies evolved from β 2 AR bronchodilators to inhaled
corticosteroids±β 2 AR therapy.•New asthma pharmacotherapy recognizes the potential of …

Introduction: Current therapies for chronic obstructive pulmonary disease (COPD) focus on
the improvement of clinical symptoms via the use of bronchodilators: β2-adrenoreceptor …

This paper describes the successful design and development of dual pharmacology β-2
agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using …